Evidence map›Paper›PMID 41603647›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2026

Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by α-Synuclein Status in Sporadic and Genetic Parkinson's Disease.

Michael Tran Duong, Sandhitsu R Das, Pulkit Khandelwal, Joaquin A Vizcarra, Yue Li, Long Xie, Paul A Yushkevich, Leslie M Shaw, Jacob G Dubroff, Parkinson's Progression Markers Initiative and 3 more

Abstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michael Tran DuongDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0312-5530
Sandhitsu R DasDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pulkit KhandelwalDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Joaquin A VizcarraDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Yue LiDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Long XieDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Paul A YushkevichDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Leslie M ShawDepartments of Medicine, Neurology and Psychiatry, Alzheimer's Disease Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jacob G DubroffDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Parkinson's Progression Markers Initiative
Andrew SiderowfDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
David A WolkDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ilya M NasrallahDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

Characterization of relationship between tau pathology and neurodegeneration in Alzheimer's disease using multimodal imagingR01AG072796 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Sandhitsu Das, DAVID A WOLK · 2022 to 2026
$4.0M
Improving the sensitivity and specificity of MRI-based biomarkers in Alzheimer's diseaseR01AG069474 · NIA · UNIVERSITY OF PENNSYLVANIA · PI WOLK, DAVID A, YUSHKEVICH, PAUL A. · 2024 to 2025
$1.4M
Alzheimer's Disease Core Center P30-AG072979Institute for Translational Medicine and Therapeutics pilot UL1-TR001878Michael J. Fox FoundationNational Institutes of Health (NIH) F30-AG074524National Institutes of Health (NIH) R01-AG072796National Institutes of Health (NIH) T32-NS091006-10NIA NIH HHS R01 AG069474NIA NIH HHS R01 AG072796
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is characterized by predominantly neuronal α-synuclein pathology and dopaminergic dysfunction. Cerebrospinal fluid (CSF) seeding amplification assays (SAA) detect α-synuclein aggregates in vivo, but not all patients with PD have a positive SAA. This pathological heterogeneity among patients may not be entirely captured by binary results from α-synuclein SAA positivity (S+) versus negativity (S-). To further dissect this biological variability, we explored spatial neuroimaging differences in S+ versus S- patients.

objectiveThe study aim was to investigate how SAA status influences imaging measures of dopamine denervation and atrophy.

methodsWe compare SAA status with CSF proteinopathy markers,

resultsBetween 64% and 95% of participants in these groups have S+ status. For all groups, S+ participants have decreased putamen DAT neurotransmission compared to S- participants, whereas S- participants have reduced MRI volume in basal ganglia structures relative to S+ participants. With striatal DAT/MRI ratios, S+ participants have disproportionately lower putamen DAT uptake relative to atrophy. In exploratory analyses, participants with cognitive impairment or hyposmia are associated with worse DAT/MRI discordance. By CSF markers, S- participants with sporadic PD have higher CSF pTau

conclusionsS+ patients exhibit more dopaminergic deficit, whereas S- patients have more subcortical atrophy across sporadic and genetic PD. Together, our findings reveal structure/function and DAT/MRI discordance, providing insight into biomarkers and pathophysiology of synucleinopathy and PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

alpha-SynucleinDopamineParkinson DiseaseAgedAmyloid beta-PeptidesAtrophyBiomarkersBrainDopamine Plasma Membrane Transport ProteinsDopaminergic ImagingFemaleHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Magnetic Resonance ImagingMaleMiddle Agedalpha-SynucleinAmyloid beta-PeptidesBiomarkersDopamineDopamine Plasma Membrane Transport ProteinsioflupaneLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanNortropanesDATMRIParkinson's diseaseSAAα‐synuclein

Identifiers

PMID41603647
PMCPMC13206170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.